MedImmune Expands Oncology Pipeline With Therapeutic Protein Technology
This article was originally published in The Pink Sheet Daily
Agreement with Avidia is firm's eleventh licensing deal or acquisition of validated targets for product development in the last 12 months.
You may also be interested in...
Committee to revisit drugs with postmarketing commitments previously reviewed in 2003 and give advice for conduct of confirmatory studies for sponsors with newly approved drugs.
Abbott will release co-promotion rights for the respiratory syncytial virus therapy effective June 30, 2006.
Newly promoted VP David Parkinson, MD, will oversee reconfigured oncology unit with separate supportive care and therapeutics groups.